Barclays analyst Balaji Prasad lowered the firm’s price target on Viatris (VTRS) to $9 from $12 and keeps an Underweight rating on the shares. The stock fell 15% on the Indore Facility impacting the 2025 outlook, the analyst tells investors in a research note. The firm says the path for stock recovery is challenging until this is resolved.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS: